Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting
Presentations highlight key attributes of plazomicin, Achaogen’s novel antibacterial against aminoglycoside-resistant and carbapenem-resistant Enterobacteriaceae
SOUTH SAN FRANCISCO, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced six upcoming presentations on plazomicin at the American Society for Microbiology (ASM) Microbe 2016 Annual Meeting. The Company and its collaborators will make two oral presentations and present four posters at the event, which will be held at the Boston Convention and Exhibition Center (BCEC) from June 16 to 20, 2016. Achaogen is developing plazomicin, its lead product candidate, to treat serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Titles and details of the presentations are provided below.
| Oral Presentations: | |
| Title: | Occurrence of Aminoglycoside Modifying Enzymes and 16s RNA Methylases |
| Among Enterobacteriaceae and Activity of Plazomicin Against Common | |
| Resistance Mechanisms | |
| Session: | New Insights on Emerging Resistance Mechanisms in Gram-negatives |
| (Session #128) | |
| Date &Time: | Saturday, June 18, 2016, 8:15 – 10:45am EDT |
| Location: | Renaissance Boston Waterfront Hotel, Atlantic Ballroom 1 |
| Authors: | Castanheira, Davis, Doyle, Mendes, Jones; JMI Lab, North Liberty, IA |
| Title: | Tolerance to Ceftazidime/Avibactam, Plazomicin and Colistin among |
| Klebsiella pneumoniae carbapenemase-producing K. pneumoniae | |
| Session: | Carbapenemases (Session #205) |
| Date &Time: | Saturday, June 18, 2016, 2:45 – 5:15pm EDT |
| Location: | BCEC, Meeting Room 156A |
| Authors: | Haidar, Clancy, Chen, Kreiswirth, Nguyen; University of Pittsburgh, Pittsburgh, |
| PA and The Public Health Research Institute at the International Center of | |
| Public Health, Newark, NJ | |
| Poster Presentations: | |
| All posters will be included in Session #424 (Tetracyclines, Aminoglycosides, and Related Compounds) on | |
| June 20, 2016 from 12:30 – 2:30pm ET at BCEC, Exhibit and Poster Halls A and B. | |
| Title: | A Comprehensive Study of Plazomicin Activity against a Panel of |
| Aminoglycoside Resistance Enzymes (Abstract #572) | |
| Authors: | Cox, Ejim, Sieron, Serio, Krause, Wright; McMaster University, Hamilton Ont., |
| Canada, Achaogen, San Francisco, CA | |
| Title: | In Vitro Activity of Plazomicin Against 110 Carbapenemase-Producing |
| Enterobacteriaceae Clinical Isolates (Abstract #554) | |
| Authors: | Zhang, Kashikar, Lin, Bush; Indiana University, Bloomington, IN |
| Title: | Activity of Plazomicin in Combination with Other Antibiotics Against |
| Multidrug Resistant Enterobacteriaceae (Abstract #570) | |
| Authors: | Thwaites, Hall, Shinabarger, Serio, Krause, Pillar; Micromyx, Kalamazoo, MI, |
| Achaogen, San Francisco, CA | |
| Title: | An Evaluation of the Bactericidal Activity of Plazomicin and Comparators |
| Against Multidrug Resistant Enterobacteriaceae (Abstract #571) | |
| Authors: | Thwaites, Hall, Shinabarger, Serio, Krause, Pillar; Micromyx, Kalamazoo, MI, |
| Achaogen, San Francisco, CA | |
The abstracts can be accessed through the ASM Microbe website. Following the meeting, all posters presented by Achaogen will be available as PDF files on the Achaogen website at www.achaogen.com.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Investor Contact: Hans Vitzthum 212.915.2568 hans@lifesciadvisors.com Media Contact: Denise Powell 510.703.9491 denise@redhousecomms.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
